Abstract
This dose-finding study of osimertinib aimed to investigate the safety, pharmacokinetics (PK), and recommended dose (RD) for EGFR-mutated non-small cell lung carcinoma (NSCLC) patients with impaired renal function and low body weight.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
